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from the abovementioned studies (Laouar
et al., 2003; Onai et al., 2006; Esashi et al.,
2008) are summarized in Figure 1.
What are the implications of differential
cytokine- and downstream STAT-regu-
lated DC development in vivo, and specif-
ically, in which situation is cDC develop-
ment at cost of pDC development
biologically beneficial? Whereas respec-
tive receptor expression is relatively re-
stricted to hematopoietic cells, Flt3 ligand
is broadly expressed in steady state by
multiple tissue stromal cells and by acti-
vated T cells; GM-CSF is produced by
some stromal cells as well as activated T
and NK cells, and macrophages; and
main sources of M-CSF include stromal
cells and endothelial cells, as well as
macrophages. All three cytokine amounts
increase in serum upon systemic inflam-
mation, for example in some infections
or autoimmune diseases, and upon
hematopoietic challenge, such as irradia-
tion-induced cytopenia. Less is known,
however, on local cytokine amounts in
a dynamically changing environment.
Thus, in contrast to controlled in vitro
situations in which cytokines effects are
studied under exclusive and probably sat-
urating conditions, DC progenitors in vivo
are exposed to subtle gradient changes
that, once a threshold is reached, will
probably shape their differentiation fate.
The study published here provides an
exciting step forward in envisioning the
in vivo situation and, as also suggested
by the authors, might guide in develop-
ing therapeutic approaches, for example
to diseases in which pDC excess is of
pathogenetic relevance.
REFERENCES
Esashi, E., Wang, Y.H., Perng, O., Liu, Y.J., and
Watowich, S.S. (2008). Immunity 28, this issue,
509–520.
Fancke, B., Suter, M., Hochrein, H., and O’Keeffe,
M. (2008). Blood 111, 150–159.
Gilliet, M., Boonstra, A., Paturel, C., Antonenko, S.,
Xu, X.L., Trinchieri, G., O’Garra, A., and Liu, Y.J.
(2002). J. Exp. Med. 195, 953–958.
Laouar, Y., Welte, T., Fu, X.Y., and Flavell, R.A.
(2003). Immunity 19, 903–912.
McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel,
K., De Smedt, T., Maraskovsky, E., Maliszewski,
C.R., Lynch, D.H., Smith, J., Pulendran, B., et al.
(2000). Blood 95, 3489–3497.
Onai, N., Obata-Onai, A., Schmid, M.A., Ohteki, T.,
Jarrossay, D., and Manz, M.G. (2007). Nat. Immu-
nol. 8, 1207–1216.
Onai, N., Obata-Onai, A., Tussiwand, R., Lanza-
vecchia, A., and Manz, M.G. (2006). J. Exp. Med.
203, 227–238.
Schiavoni, G., Mattei, F., Sestili, P., Borghi, P.,
Venditti, M., Morse, H.C., 3rd, Belardelli, F., and
Gabriele, L. (2002). J. Exp. Med. 196, 1415–1425.
Shortman, K., and Naik, S.H. (2007). Nat. Rev.
Immunol. 7, 19–30.
Zenke, M., and Hieronymus, T. (2006). Trends
Immunol. 27, 140–145.
Immunity
PreviewsCancer Immunosurveillance: NKG2D Breaks Cover
Hans-Gustaf Ljunggren1,*
1Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden
*Correspondence: hans-gustaf.ljunggren@ki.se
DOI 10.1016/j.immuni.2008.03.007
The idea of cancer immunosurveillance has regained interest in recent years. In this issue of Immunity, Guerra
et al. (2008) present the first genetic evidence for surveillance of primary tumors by a natural killer cell-asso-
ciated receptor.Since their discovery, a large number of
studies have demonstrated natural killer
(NK) cell-mediated lysis of different types
of tumor cells in vitro, as well as NK cell-
dependent elimination of many tumors
in vivo. For a long time, it was unknown
how NK cells recognized tumor cells, as
well as other aberrant cells. Over the last
15 years, however, a large number of
germline-encoded NK cell-activation and
-inhibitory receptors have been discov-
ered (Lanier, 2005). NK cell-inhibitory re-
ceptors, most of which recognize major
histocompatibility complex (MHC) class I
molecules, were the first NK cell receptors
to be identified. After the discovery of
these, a large number of different NK492 Immunity 28, April 2008 ª2008 Elseviercell-activating receptors were described.
Among these, ‘‘natural killer group 2,
member D’’ (NKG2D) is one of the most
well characterized receptors. The identifi-
cation of NKG2D and other activation
receptors has provided detailed insight
into the activation of NK cells upon tar-
get-cell recognition (Bryceson et al.,
2006). In this issue of Immunity, Guerra
et al. (2008) describe the phenotype of
NKG2D-deficient mice and provide the
first genetic evidence for surveillance of
spontaneous tumor development by the
NKG2D receptor.
NKG2D is a type II transmembrane-an-
chored glycoprotein expressed as a disul-
fide-linked homodimer on the surface ofInc.almost all NK cells. NKG2D is also ex-
pressed on some CD8+ ab+ T cells, NKT
cells, gd+ T cells, and on a small subset
of CD4+ ab+ T cells. In humans, NKG2D
binds to the cellular stress-inducible
molecules MHC class I chain-related A
(MICA) and MICB and members of the
UL-16-binding protein (ULBP) family. In
mice, NKG2D binds to a family of several
Rae1 proteins, the minor histocompatibil-
ity protein H60, and the murine UL-16-
binding protein-like transcript 1 (MULT1)
(Eagle and Trowsdale, 2007). NKG2D
ligands are frequently expressed on pri-
mary tumor cells, tumor cell lines, and
some cells infected with pathogens. A
DNA-damage pathway regulates NKG2D
Immunity
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Ligand-expressing cells can activate
NKG2D-expressing NK cells and T cells
in vitro, and ligand-transfected tumor
cells have been shown to be rejected
in vivo in an NKG2D-dependent fashion.
Thus, a series of recent findings indicates
that the NKG2D receptor may play an
important role in tumor recognition (Haya-
kawa and Smyth, 2006). These studies
indicate that immunological recognition
of developing tumors in the host may
result not only from the recognition of spe-
cific antigens presented by MHC class I
and II molecules but also by cellular-
stress-induced ligands expressed on
transformed cells but not on normal cells.
In the present issue of Immunity, Guerra
et al. (2008) describe the generation
and characterization of NKG2D-deficient
mice. These mice provide an important
tool to study directly the surveillance of
primary tumors by the NKG2D receptor.
NKG2D-deficient mice, generated on
a C57BL/6 background, develop nor-
mally. They have normal numbers and
proportions of lymphocytes, indicating
that NKG2D is dispensable for normal
lymphoid development. With the excep-
tion of NKG2D, expression of several acti-
vation and inhibitory receptors is similar to
that in wild-type mice. Furthermore,
although NKG2D-deficient NK cells are
defective in NKG2D function, they retain
other NK cell functions. The latter include
NKG2D-independent cytotoxicity against
various tumor cell lines and responsive-
ness to direct crosslinking of activation
receptors (other than NKG2D). Thus, acti-
vating functions of various stimulatory NK
cell receptors are unaffected by the lack
of NKG2D. NKG2D-deficient mice also
mediate ‘‘missing-self’’ recognition of b2
m-deficient bone marrow grafts, suggest-
ing that NKG2D is dispensable in the
rejection of bone marrow grafts in this
particular genetic setting. Taken together,
NKG2D deficiency does not globally
impair NK cell function in vivo.
To determine whether NKG2D defi-
ciency promotes the development of
spontaneous tumors, Guerra et al. (2008)
first introduced the NKG2D deficiency
into the transgenic adenocarcinoma of
the mouse prostate (TRAMP) model of
autochthonous prostate cancer develop-
ment (Kaplan-Lefko et al., 2003). Strik-
ingly, early-arising aggressive prostate tu-
mors were three times more frequent inFigure 1. NK Cells Lacking Expression of the Activating Receptor NKG2D Fail to Recognize
Transformed Epithelial Cells Expressing Rae-1 Proteins
Transformation of normal epithelium and other cell types often leads to the expression of ligands for the
activation receptor NKG2D. In mice, such ligands belong to a family of several Rae1 as well as H60 and
MULT1 proteins. The figure illustrates the rejection of tumor cells expressing NKG2D ligands by NK cells.
In the absence of the NKG2D receptor, these tumors cannot be rejected by NK cells or other NKG2D-ex-
pressing immune cells. The result is aggressive tumor development, as illustrated by Guerra et al. (2008) in
this issue of Immunity.NKG2D-deficient TRAMP mice than in
wild-type TRAMP mice (Figure 1). Histo-
pathological examination of tumors aris-
ing in NKG2D-deficient mice confirmed
a highly malignant status of the early-aris-
ing tumors. These findings demonstrate
that an NKG2D-mediated immune mech-
anism limits the development of the most
aggressive form of prostate cancer in
TRAMP mice of the C57BL/6 back-
ground. In contrast, the percentages of
visible metastasis were similar in NKG2D-
deficient mice and wild-type mice. This
outcome suggests the possibility that
NKG2D functions primarily at an early
stage of tumorigenesis rather than at the
stage of metastasis, at least in this model
of spontaneous prostate cancer. Interest-
ingly, NKG2D deficiency was associated
also with preB-B cell lymphoma develop-
ment. The latter was incited by Guerra
et al. (2008) by introduction of the
NKG2D deficiency into transgenic Em-
myc mice (Adams et al., 1985). Myc-
driven lymphomas arose substantially
earlier in NKG2D-deficient Em-myc mice
than in wild-type Em-myc mice. These
results indicate that NKG2D is critical for
immunosurveillance not only of early epi-Immthelial but also of lymphoid malignancies.
Notably, however, genetic NKG2D defi-
ciency does not seem to affect the inci-
dence of carcinogen-induced sarcomas.
These findings contrast to findings where
mice treated with a neutralizing NKG2D
antibody had a greater incidence of car-
cinogen-induced carcinomas (Hayakawa
and Smyth, 2006).
Tumor development may be viewed as
an evolutionary process, involving selec-
tion of mutants and regulation of specific
molecules for the advantage of the tumor
on behalf of the host. In this respect, the
immune system may select for tumor var-
iants that survive better in an immunolog-
ically intact environment (Dunn et al.,
2006). Interestingly, the observations by
Guerra et al. (2008) are in line with this
notion. In the TRAMP mice, NKG2D-
ligand expression is largely restricted to
the smaller late-arising tumors but absent
from the large early-arising ones. This re-
sult suggests the possibility that large, ag-
gressive early-arising TRAMP tumors ex-
tinguish expression of NKG2D ligands as
a result of NKG2D-dependent immunose-
lection or editing. Consistent with this
finding, substantially higher expressionunity 28, April 2008 ª2008 Elsevier Inc. 493
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large aggressive tumors fromNKG2D-de-
ficient TRAMP mice than wild-type
TRAMP mice. Combined, these observa-
tions suggest that NKG2D-dependent
immunoediting favors loss of NKG2D
ligands on early-arising, aggressive tu-
mors. Smaller, late-arising tumors, in con-
trast, do not seem to be subject to the
same type of immunoediting.
Guerraetal. (2008) have focused primar-
ily on tumor progression in NKG2D-defi-
cient mice crossed to transgenic models
of spontaneous cancer development. In
both spontaneous tumor models studied,
it will be of interest to study in the relative
role of different NKG2D-expressing lym-
phocyte subpopulations (T cell subsets
and NK cells) in resistance to spontane-
ous tumor development. It will also be of
interest to study the tumorigenicity of
NKG2D-edited versus nonedited tumors,
i.e., tumors that have, or have not, lost ex-
pression NKG2D ligands during tumor
progression. Another interesting question
for future studies is whether aging
NKG2D-deficient mice will succumb to
higher incidence of spontaneous tumor
development. Infection of cells by a num-
ber of viruses, including human cytomeg-
alovirus (HCMV), murine cytomegalovirus
(MCMV), Influenza A, and Epstein-Barr
virus (EBV), is known to induce NKG2D-
ligand expression (Eagle and Trowsdale,
2007). Both HCMV and MCMV deploy
immunoevasin proteins that to different
degrees prevent expression of NKG2D
ligands on the surface of infected cells.
However, each immunoevasin has a lim-
ited capacity to bind NKG2D ligands. In
light of this and related questions, it will
be of interest to study how NKG2D-defi-494 Immunity 28, April 2008 ª2008 Elseviercient mice handle infections with viruses
such asMCMV. Finally, it will also be of in-
terest to study whether genetic NKG2D
deficiency is associated with altered auto-
immune, hypersensitivity, and transplant
rejection responses.
Overwhelming evidence now supports
the concept of immune control of tumor
development (Dunn et al., 2006; Haya-
kawa and Smyth, 2006). Refined experi-
mental models of cancer, new models of
defined immunodeficiency, and insights
into the molecular specificity and function
of host immune cells have contributed
significantly to this conclusion. The obser-
vations presented by Guerra et al. (2008)
represent an excellent illustration of this
phenomenon in the mouse system. The
present observations are also interesting
in relation to human cancer. In the future,
it is not unlikely that more cancers will be
treated with drugs or other immunomodu-
latory agents that affect NK cells (or other
immune cells), either directly or indirectly.
Certain forms of cancer may also be sub-
ject to treatment with adoptively trans-
ferred NK cells (Ljunggren and Malmberg,
2007). The status of NKG2D-ligand ex-
pression on target tumor cells may be
one critical factor for the prediction of
the responsiveness to NK cell-dependent
immunotherapy. Cancer treatment may
also involve novel strategies to induce the
expression of ligands for activating im-
mune receptors, such as NKG2D ligands,
in tumors. Interestingly, several of the cur-
rently used chemotherapeutic drugs as
well as ionizing irradiation act through
the DNA-damage-response pathway that
enhances the expression of ligands for
NKG2D (Gasser et al., 2005). Thus, a rea-
sonable prediction is that treatment mo-Inc.dalities designed to affect NKG2D-ligand
expression in tumors, used in combina-
tion with strategies to enhance NK cell ef-
fector functions or NK cell-based adop-
tive immunotherapy, lie in the horizon of
new prospects for fighting cancer. In con-
clusion, the field of tumor immunity is rap-
idly gaining precise information about the
delicate interplay between evolving tu-
mors and specific host immune reactions.
New findings promise not only to clarify
tumor-immune interactions at a molecular
level but also to provide superior treat-
ment strategies for overcoming human
cancer.
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